Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,132.19 -7.07 -0.23%
FTSE 100 6,568.39 -15.78 -0.24%
DAX 9,292.46 -25.36 -0.27%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,667.12 -28.89 -0.13%

At Six Months Post-Launch, the User-Base of Pfizer's Xeljanz for Rheumatoid Arthritis Has Nearly Doubled Since Three Months Post

 At Six Months Post-Launch, the User-Base of Pfizer's Xeljanz for Rheumatoid
         Arthritis Has Nearly Doubled Since Three Months Post-Launch

However, the Low Number of Reported Average Initiations Among Xeljanz Users
Suggests that U.S. Rheumatologists Are Still Trialing the Product in RA
Patients, According to a New Report from BioTrends Research Group

PR Newswire

EXTON, Pa., July 25, 2013

EXTON, Pa., July 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that at six months post-launch, the user-base of Pfizer's
Xeljanz—the newest treatment for rheumatoid arthritis (RA)—has nearly doubled,
compared to previous research fielded three months post-launch. The six-month
trial rate among rheumatologists is 61 percent compared to 32 percent three
months ago. Although 61 percent of surveyed rheumatologists report trial of
the product, users of Xeljanz have only initiated treatment in an average of
six RA patients, with three-quarters of the user-base reporting initiation of
Xeljanz in five or fewer patients. The LaunchTrends^®: Xeljanz, Wave 3 (US)
report also finds that surveyed rheumatologists anticipate these numbers will
increase in the future.


"Based on the study data, Xeljanz trial rates are anticipated to increase to
72 percent in the next month," said BioTrends Research Group Associate
Director of Immunology Lynn Price. "Furthermore, these physicians are
expecting to initiate an additional three RA patients on Xeljanz in the next
month, increasing both the user- and patient-base for Xeljanz."

According to the report, surveyed rheumatologists indicate that the majority
of RA patients currently treated with Xeljanz have moderate-to-severe disease
and have been switched from another agent, most commonly from an anti-TNF
biologic. However, the percentage of Xeljanz patients who are biologic naive
has significantly increased, with rheumatologists reporting approximately
one-quarter of current Xeljanz patients as biologic-naive prior to initiation,
significantly more than 13 percent reported at three months post-launch.

The recently published report also finds that over three-quarters of current
Xeljanz users are moderately-to-highly satisfied with the product, generally
citing that their high satisfaction is attributed to patients having an
initial positive response, the drug's quick onset of action and patients
experiencing little to no tolerability issues. Additionally, reported Xeljanz
discontinuation rates are low, with approximately one in ten patients
initiated on Xeljanz having to discontinue use. The most common reasons for
Xeljanz discontinuation are patient request, tolerability issues and safety

LaunchTrends^®: Xeljanz, Wave 3 (US) is a four-wave syndicated report series
designed to track the uptake of Xeljanz at one month, three months, six months
and one year following its commercial availability based upon primary research
with U.S. rheumatologists. LaunchTrends assess trial and use of new products,
obstacles to use, reasons to use, typical patient types, line of therapy,
product perceptions, promotional efforts/messages and product satisfaction. In
the current wave of research, BioTrends surveyed 72 U.S. rheumatologists in
May 2013 and conducted qualitative interviews with a subset of 15 of the
respondents in May/June 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at BioTrends
is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group

Sponsored Links
Sponsored Links